ArticleTranslational cancer research2026
Efficacy and potential mechanism of main active ingredients of
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatic carcinoma (HCC) is a malignant tumor. This systematic review and meta-analysis aimed to explore the efficacy and possible mechanism of the main active ingredients of Methods: The study retrieved eight databases [PubMed, Web of Science, Embase, China Biomedical Literature Database (CBM), Cochrane Library, Wanfang Database (Wanfang), China Science and Technology Journal Database (VIP), and China National Knowledge Infrastructure (CNKI)]. The evaluation of methodological quality was conducted utilizing the risk of bias tool (SYRCLE). The study chose RevMan 5.4 for statistical analysis. Results: Fifty-three studies involving 1,110 animals were selected. The risk of bias in studies was rated as low, medium, or high. Low-dose AM [n=140; standardized mean difference (SMD), -5.03; 95% confidence interval (CI): -6.95 to -3.10, low certainty] and high-dose AM (n=149; SMD, -5.80; 95% CI: -8.26 to -3.34, low certainty) reduced tumor volume. Meta-analysis indicated that the AM's main active components exerted a beneficial effect on various indicators in HCC animals, including alanine aminotransferase (ALT) (n=156; SMD, -3.95; 95% CI: -6.13 to -1.78, low certainty), aspartate aminotransferase (AST) (n=126; SMD, -5.91; 95% CI: -9.00 to -2.82, low certainty), alkaline phosphatase (ALP) (n=80; SMD, -0.69; 95% CI: -1.80 to -0.42, low certainty), interleukin 2 (IL-2) (n=136; SMD, 2.88; 95% CI: 1.38 to 4.37, low certainty), interleukin 6 (IL-6) (n=95; SMD, 0.93; 95% CI: -2.05 to 3.91, low certainty), interferon-gamma (IFN-γ) (n=99; SMD, 4.67; 95% CI: 1.63 to 7.70, low certainty), and tumor necrosis factor-α (TNF-α) (n=236; SMD, 2.00; 95% CI: 0.66 to 3.33, low certainty). Conclusions: The meta-analysis certifies the effectiveness of the AM's main active ingredients in HCC based on early-phase investigations. The possible mechanism may link to inhibition of tumor weight, tumor volume, and regulation of inflammatory response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.